Financial assets
|
Subsidiaries
|
Associates and JVs
|
Other
participating interests |
Receivables
|
Total
|
|||
|
Share in equity
|
Loans
|
Share in equity
|
Loans
|
||||
|
Balance at 1 January 2017
|
9,433
|
-
|
432
|
-
|
-
|
110
|
9,975
|
|---|---|---|---|---|---|---|---|
|
Changes:
|
|||||||
|
- Share in profit
|
590
|
-
|
18
|
-
|
-
|
-
|
608
|
|
- Charged to income statement
|
-
|
-
|
-
|
-
|
-
|
30
|
30
|
|
- Dividend received
|
(80)
|
-
|
-
|
-
|
-
|
-
|
(80)
|
|
- Capital payments
|
11
|
-
|
-
|
-
|
-
|
-
|
11
|
|
- Repayments
|
-
|
-
|
-
|
-
|
-
|
(43)
|
(43)
|
|
- Net actuarial gains/(losses)
|
61
|
-
|
-
|
-
|
-
|
-
|
61
|
|
- Change in Fair value reserve
|
(3)
|
-
|
-
|
-
|
-
|
-
|
(3)
|
|
- Change in Hedging reserve
|
35
|
-
|
5
|
-
|
-
|
-
|
40
|
|
- Exchange differences
|
(591)
|
-
|
(47)
|
-
|
-
|
(6)
|
(644)
|
|
- Disposals
|
-
|
-
|
(249)
|
-
|
-
|
-
|
(249)
|
|
- Impairments
|
-
|
-
|
(20)
|
-
|
-
|
-
|
(20)
|
|
- Others
|
(47)
|
-
|
1
|
-
|
-
|
-
|
(46)
|
|
Balance at 31 December 2017
|
9,409
|
-
|
140
|
-
|
-
|
91
|
9,640
|
|
Changes:
|
|||||||
|
- Share in profit
|
1,054
|
-
|
11
|
-
|
-
|
-
|
1,065
|
|
- Charged to income statement
|
-
|
-
|
-
|
-
|
-
|
(33)
|
(33)
|
|
- Dividend received
|
(198)
|
-
|
-
|
-
|
-
|
-
|
(198)
|
|
- Capital payments
|
49
|
-
|
-
|
-
|
-
|
-
|
49
|
|
- Repayments
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
- Net actuarial gains/(losses)
|
(66)
|
-
|
-
|
-
|
-
|
-
|
(66)
|
|
- Change in Fair value reserve
|
15
|
-
|
-
|
-
|
1
|
-
|
16
|
|
- Change in Hedging reserve
|
(38)
|
-
|
(2)
|
-
|
-
|
-
|
(40)
|
|
- Exchange differences
|
138
|
-
|
-
|
-
|
-
|
-
|
138
|
|
- Disposals
|
-
|
-
|
(144)
|
-
|
-
|
-
|
(144)
|
|
- Other
|
44
|
-
|
(5)
|
-
|
36
|
(22)
|
53
|
|
Balance at 31 December 2018
|
10,407
|
-
|
-
|
-
|
37
|
36
|
10,480
|
For movements in Associates and joint arrangements, Note 10 to the 'Consolidated financial statements'.
Disposals in 2018 relate to the divestment of DSM's share in DSM Sinochem Pharmaceuticals. Disposals in 2017 relate to the divestment of DSM's share in Patheon, including the settlement of the earn-out receivable. See Note 10 to the 'Consolidated financial statements'.